New Delhi, 24/4 (AO bureau):
Serum Institute of India, which is facing criticism over the price of the Corona Virus Vaccine Covishield, issued a press release on Saturday. The company said in a statement that the price of the vaccine has been kept very low for the government purchases for global countries including India, because the number of volumes is very large. Several vaccines are being sold at high prices in the private market, including market conditions and our pneumococcal vaccine, although for the government, one-third of its price is being sold in the free market.
The statement said that the global price of the vaccine is being compared incorrectly with India. Kovishield is the cheapest vaccine in the market today. Initially the price of this vaccine was kept very low, because many countries had funded for it, so that the vaccine could be developed by taking the risk. Along with this, Kovishield has been initially supplied to all governments including India for the vaccination program at extremely low prices.
The company has said in its statement that the current situation is very challenging. The virus is continuously mutating and public life is in danger. Given the uncertainty, we have to maintain investment to expand and expand our production. So that we can fight the epidemic with our full potential and save the lives of the people.